With no growth-drivers in the near-term, outside of minor development catalysts, any position in VRTX should be considered a long-term investment, based primarily on the potential of its cystic fibrosis program.
yeah, for 100 new people in canada, don't waste company time or resources to send a business news article out. geez, how about going after a new disease that has maybe 5 people worldwide? spend 500MM to develope a drug to make $50 bucks on worldwide. Great management. No wonder why dilbert makes tons of money writing about these jokesters.
So you own your own company bringing over $1B in revenue, curing people of a deadly disease and in another disease helping patients live better lives. You are obviously simply trying to bash the stock. The company has built itself into a great company with multiple products and there are more products in the pipeline.